It’s completely understandable to feel unsure before starting a biologic — especially when you’ve heard different experiences from different people.
Most patients with ABPA or severe Aspergillus-related asthma do very well on biologics. Side effects can happen, but they’re usually mild and settle quickly.
🌟 Most people report very few problems
Patients often say:
-
The injections are straightforward
-
They feel the same or better within days or weeks
-
There’s little or no impact on daily life
🌟 Common, mild side effects
These are the ones we hear most often across omalizumab, benralizumab, dupilumab and tezepelumab:
📌 Injection-site reactions
-
Redness
-
Itching
-
A small tender lump
-
Bruising
These usually disappear within 24–48 hours.
📌 Mild tiredness
Some people feel slightly “wiped out” after the first few doses.
📌 Headache
Very common with the first injection. Less so afterwards.
📌 Minor joint or muscle aches
A bit like the feeling after a flu jab.
📌 Nasal or sinus changes
Occasional mild dryness or congestion, especially with dupilumab.
🌟 Less common (still mild)
-
Mild tummy upset
-
Sore throat
-
A brief “flu-ish” feeling
-
Temporary increase in eczema (mainly with dupilumab)
-
Slight mood dip for a day or two (rare)
🌟 Rare but important
These are very uncommon, and your team will explain what to look out for:
-
Allergic reaction shortly after an injection
(This is why your first dose is supervised.) -
Eye inflammation — mostly linked to dupilumab, usually mild and treatable
Your team will give you clear advice on what to do if anything unusual happens.
🌟 What ABPA patients often notice
People with ABPA frequently describe:
👉 Fewer allergic symptoms
👉 Clearer breathing
👉 Much less mucus
👉 Fewer flare-ups and fewer steroids
But biologics don’t help everyone — which is why the first few months are monitored closely.
🌟 Final reassurance
For many aspergillosis patients, biologics are far easier than long-term steroids or antifungals. Most say the benefits outweigh the side effects — but every person’s experience is individual.
Share this post
Latest News posts
Recent Aspergillosis Research – January 2026 (week 2)
January 16, 2026
Sinusitis in Patients with ABPA
January 16, 2026
Hydrocortisone dosing in adrenal insufficiency
January 5, 2026
Season’s Greeting
December 24, 2025
News archive
- ABPA
- Air Quality
- Airway Clearance, Diagnosis & Physiotherapy
- Antifungals
- Aspergilloma
- Aspergillus Bronchitis
- Biologics
- CPA
- Carers & Family
- Communities
- Complementary & Supplements
- Complications
- Conditions
- Diagnostics
- Environment
- Events & Recordings
- GP Guidance
- General interest
- Housing & Damp
- Imaging
- Immune System
- Lifestyle & Coping
- Living with Aspergillosis
- Mental Health
- Monitoring
- Monitoring & Safety
- NAC & Guidance
- NAC Announcements
- Professional Guidance
- Recordings
- Research
- Research Summaries
- SAFS / Severe Asthma
- Side Effects
- Steroids
- Symptoms
- Travel and Insurance
- Treatment
- Vaccines
- Weekly Updates
